Attovia Therapeutics

Executive Summary

Attovia Therapeutics is a preclinical-stage biotechnology company founded in 2022 and headquartered in Fremont, California. The company is pioneering novel multispecific biologics for immune-mediated diseases with high unmet medical need. Its core technology is the proprietary ATTOBODY platform, which enables the modular design of precision medicines capable of engaging multiple disease pathways simultaneously. This approach aims to improve efficacy and reduce resistance compared to traditional monoclonal antibodies. Attovia is currently in the early stages of development, with no disclosed pipeline candidates or funding history, indicating a high-risk, high-reward profile typical of early biotech ventures.

Upcoming Catalysts (preview)

• Q4 2026Nomination of lead candidate for first ATTOBODY program30% success
• Q1 2027Series A financing round to advance platform50% success
• H2 2026Presentation of preclinical proof-of-concept data at a major conference40% success